The percentage on each card is CGEM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● Seeking AlphaNov 17, 2026 · 16:33 ET
Cullinan Therapeutics, Inc. (CGEM) Presents at UBS Global Biopharma Conference 2026 Transcript
Cullinan Therapeutics, Inc. ( CGEM ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Nadim Ahmed - President, CEO & Director Jeffrey Jones - Chief Medical Officer Conference Call P…
● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren's disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimmune cytopenias initi…
● GlobeNewsWireNov 4, 2026 · 09:14 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers…
● Zacks Investment ResearchOct 29, 2026 · 10:55 ET
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in r…
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monot…
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could hel…
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentation…
● GlobeNewsWireSep 24, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE) updated data from the …
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM
Engineers Gate Manager LP raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 130.9% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Co…
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engager…
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e…
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, Septe…
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset
Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestone…
Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEM
Bank of America Corp DE lifted its stake in Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 49.2% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutiona…
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC PRINCET…
Article counts from the last market-wide feed page, across every symbol we track and not just CGEM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.